Skip to main content

Table 3 Association of PCSK9 E670G polymorphism and CAD risk

From: Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population

   

CAD (n)

Controls (n)

Crude OR (95% CI)

P

Adjusted OR (95% CI)

P @

All

 

AA

567

417

0.819 (0.553–1.212)

0.317

0.838 (0.548–1.280)

0.414

AG + GG

59

53

Gender

Male

AA

396

220

0.960 (0.564–1.636)

0.882

0.952 (0.541–1.675)

0.864

AG + GG

43

23

Female

AA

171

197

1.636 (0.862–3.104)

0.132

0.706 (0.345–1.445)

0.341

AG + GG

16

30

Age

≥ 60 (years)

AA

407

268

0.850(0.530–1.365)

0.501

0.790(0.363–1.509)

0.407

AG + GG

44

34

< 60 (years)

AA

159

149

0.740(0.363–1.509)

0.407

0.896(0.408–1.970)

0.785

AG + GG

15

19

EH

Yes

AA

415

244

0.717 (0.437–1.174)

0.186

0.688 (0.406–1.165)

0.164

AG + GG

39

32

No

AA

152

173

1.084 (0.566–2.076)

0.808

1.260 (0.586–2.709)

0.554

AG + GG

20

21

DM

Yes

AA

149

57

0.946 (0.583–1.532)

0.820

0.497 (0.193–1.278)

0.147

AG + GG

14

10

No

AA

418

360

0.901 (0.580–1.401)

0.644

0.536 (0.225–1.275)

0.158

AG + GG

45

43

Smoking

Yes

AA

219

105

1.065 (0.469–2.420)

0.880

1.055 (0.443–2.512)

0.903

AG + GG

20

9

No

AA

348

312

0.795 (0.503–1.255)

0.325

0.834 (0.498–1.397)

0.490

AG + GG

39

44

  1. CAD coronary artery disease, OR odds ratio, CI confidence interval
  2. @Aadjustment with age, gender, smoking, EH, DM and lipid profiles